04Aug
09Jul
Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors
Corbus Pharmaceuticals, a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (ECS), today announced the appointment of George Golumbeski, Ph.D., to its Board of Directors. Read more >>
23Jun
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that the last subject completed their final visit in the Company’s Phase 2b JBT101-CF-002 trial of lenabasum for the treatment of cystic fibrosis. Read more >>
23May
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the publication of two abstracts at the European League Against Rheumatism (EULAR) 2020 E-Congress that will be taking place June 3-6, 2020. Read more >>
15May
Collaborating on Rare Disease R&D
This week on Growing Greater we learn of rare and serious systemic autoimmune condition known as dermatomyositis. We learn of Corbus Pharmaceuticals’ collaboration with University of Pennsylvania on a Phase 2 study, which has shown positive results. Read more >>
30Apr
Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (ECS), today announced the publication of results from the double-blind, randomized, placebo-controlled Phase 2 trial assessing the safety and efficacy of lenabasum in 42 patients with diffuse cutaneous systemic sclerosis in Arthritis & Rheumatology. Read more >>
09Apr
Norwood Hospital Receives 200 Lunches From Pharmaceutical Company
Norwood-based company, Corbus Pharmaceuticals, donated masks and 200 lunches to the staff at Norwood Hospital to support health care workers and staff who are on the front lines of providing care amid the coronavirus pandemic. Read more >>
11Mar
Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the appointment of Pete Salzmann, M.D., MBA, to its Board of Directors. Dr. Salzmann brings 20 years of industry experience and currently serves as Chief Executive Officer of Immunovant (IMVT), a biopharmaceutical company focused on developing therapies for patients with autoimmune diseases. Read more >>
07Feb
Corbus Pharmaceuticals Announces Proposed Public Offering of Common Stock
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it plans to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Corbus. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of...
10Dec